Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Open Access
- 13 May 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 33 (7) , 2085-2092
Abstract
Cancer stem cells (CSCs) represent a small subset of tumor cells which have the ability to self-renew and generate the diverse cells that comprise the tumor bulk. They are responsible for local tumor recurrence and distant metastasis. However, they are resistant to conventional radiotherapy and chemotherapy. Novel immunotherapeutic strategies that specifically target CSCs may improve the efficacy of cancer therapy. To immunologically target CSC phenotypes, innate immune responses to CSCs have been reported using Natural killer cells and γδ T cells. To target CSC specifically, in vitro CSC-primed T cells have been successfully generated and shown targeting of CSCs in vivo after adoptive transfer. Recently, CSC-based dendritic cell vaccine has demonstrated significant induction of anti-CSC immunity both in vivo in immunocompetent hosts and in vitro as evident by CSC reactivity of CSC vaccine-primed antibodies and T cells. In addition, identification of specific antigens or genetic alterations in CSCs may provide more specific targets for immunotherapy. ALDH, CD44, CD133, and HER2 have served as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. Finally, since CSCs are regulated by interactions with the CSC niche, these interactions may serve as additional targets for CSC immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell, for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well as the immune checkpoint (PD1/PDL1, etc.) may provide additional novel strategies to enhance the immunological targeting of CSCs. Stem Cells 2015;33:2085–2092Keywords
Funding Information
- NIH (1R56DE024385-01)
- University of Michigan Round 10 MICHR/CTSA Pilot
- Gillson Longenbaugh Foundation
This publication has 101 references indexed in Scilit:
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cellsCellular Signalling, 2013
- IL6-Mediated Suppression of miR-200c Directs Constitutive Activation of Inflammatory Signaling Circuit Driving Transformation and TumorigenesisMolecular Cell, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumoursBritish Journal of Cancer, 2011
- Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cellsInternational Journal of Cancer, 2011
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell TransformationCell, 2009
- High Aldehyde Dehydrogenase Activity: A Novel Functional Marker of Murine Prostate Stem/Progenitor CellsStem Cells, 2009
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasionOncogene, 2008
- Identification of cells initiating human melanomasNature, 2008
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005